ライフサイエンスコーパス: enzyme immunoassay

1 nked immunosorbent assay and the competitive enzyme immunoassay.

2 gen-specific IgG antibody were quantified by enzyme immunoassay.

3 tibodies against EBV viral capsid antigen by enzyme immunoassay.

4 e concentrations were quantified by using an enzyme immunoassay.

5 TIMP-2 were quantified by protein assay and enzyme immunoassay.

6 RT-PCR, quantitative immunofluorescence, and enzyme immunoassay.

7 8) and lactoferrin protein concentrations by enzyme immunoassay.

8 arable to that of both PCR and galactomannan enzyme immunoassay.

9 ibody to HBsAg (anti-HBs) and anti-HBc using enzyme immunoassay.

10 measles immunoglobulin G (IgG) serostatus by enzyme immunoassay.

11 , 18% (78/436) by PCR, and 22.2% (98/442) by enzyme immunoassay.

12 levels were quantified by using fluorescence enzyme immunoassay.

13 s were tested using a commercial measles IgM enzyme immunoassay.

14 Intracellular cAMP levels were measured by enzyme immunoassay.

15 rotavirus was detected in fecal specimens by enzyme immunoassay.

16 cGMP was assayed by an enzyme immunoassay.

17 eactive IgG for all five GI VLPs measured by enzyme immunoassay.

18 nd the C3 split product iC3b was measured by enzyme immunoassay.

19 d transformed human TM cells, as measured by enzyme immunoassay.

20 HSV-2 serostatus at baseline using an HSV-2 enzyme immunoassay.

21 ontent in the chamber tissue was measured by enzyme immunoassay.

22 ase chain reaction, immunohistochemistry, or enzyme immunoassay.

23 and we measured products of C3 activation by enzyme immunoassay.

24 oncentrations using an 11-oxoetiocholanolone-enzyme immunoassay.

25 ected genes by reverse transcription-PCR and enzyme immunoassay.

26 Synovial levels of PBEF were quantified by enzyme immunoassay.

27 tides had been evaluated previously in a DNA enzyme immunoassay.

28 s from 514 mice were found to be positive by enzyme immunoassay.

29 and prolactin was measured by microparticle enzyme immunoassay.

30 s measured using a high-sensitivity sandwich enzyme immunoassay.

31 Histamine and leptin levels were measured by enzyme immunoassay.

32 ermined through the limiting antigen avidity enzyme immunoassay.

33 24 and 48 hours were measured by commercial enzyme immunoassay.

34 using the MVista anti-Coccidioides antibody enzyme immunoassay.

35 stools collected and tested for rotavirus by enzyme immunoassay.

36 ses) or negative (controls) for rotavirus by enzyme immunoassay.

37 a seroprotection and mumps seropositivity by enzyme immunoassay.

38 e, by Beadlyte technology (Luminex((R))) and enzyme immunoassays.

39 assessed at baseline and during follow-up by enzyme immunoassays.

40 s and testing HIV-positive on less sensitive enzyme immunoassays.

41 test and a range of agglutination assays and enzyme immunoassays.

42 ibition assay, complement fixation assay, or enzyme immunoassays.

43 lation 3, n = 61) and in healthy controls by enzyme immunoassays.

44 nd sera for antirotavirus immunoglobulins by enzyme immunoassays.

45 e tested for HHV-8 antibodies with use of an enzyme immunoassay against K8.1.

46 laboratory for KSHV antibodies with use of 2 enzyme immunoassays (against K8.1 and ORF65) and 1 immun

47 Enzyme immunoassay analysis showed that PGE2 release was

48 tudies have reported that galactomannan (GM) enzyme immunoassay and 1,3 beta-glucan (BG) assay may be

49 Enzyme immunoassay and a cytokine bead assay were used t

50 id and PF4/aptamer complexes, as shown by an enzyme immunoassay and a functional platelet activation

51 SV40 antibodies using a virus-like particle enzyme immunoassay and a plaque neutralization assay.

52 luding detection of Campylobacter species by enzyme immunoassay and Campylobacter jejuni/coli by quan

53 lutamate dehydrogenase and toxins A and B by enzyme immunoassay and cell culture cytotoxicity assay (

54 nti-inflammatory mediators using competitive enzyme immunoassay and enzyme-linked immunosorbent assay

55 Stool specimens were tested for rotavirus by enzyme immunoassay and genotyped, and rotavirus vaccinat

56 Fecal specimens were tested for rotavirus by enzyme immunoassay and genotyped.

57 ed to results obtained retrospectively using enzyme immunoassay and nucleic acid amplification tests

58 y identified 230 HCV-infected patients using enzyme immunoassay and nucleic acid testing obtained dur

59 repeat testing for Clostridium difficile by enzyme immunoassay and PCR (i.e., initial negative resul

60 Measurements included third-generation HCV enzyme immunoassay and routine laboratory measurements.

61 rmance in comparison to that of a first-tier enzyme immunoassay and the STT algorithm.

62 rmance of standard HIV antibody tests (i.e., enzyme immunoassay and Western blot analysis) with an al

63 and 60 normal controls were examined both by enzyme immunoassays and by Western immunoblotting for au

64 nsuming and requires considerable expertise; enzyme immunoassays and direct fluorescent-antibody (DFA

65 ed among these diagnostic tests are the same enzyme immunoassays and immunoblots that are routinely u

66 ple purified allergens that could be used in enzyme immunoassays and in multiplex arrays for the stan

67 ples were tested for measles IgM antibody by enzyme immunoassays and plaque reduction neutralization

68 and tissue trophic factors were measured by enzyme immunoassays and quantitative RT-PCR.

69 een testing HIV-positive on highly sensitive enzyme immunoassays and testing HIV-positive on less sen

70 d affect the detection of p24 capsid by both enzyme immunoassays and Western blots.

71 ve to nucleic acid amplification test and/or enzyme immunoassay, and determined the delay in OFOQ con

72 PCR, lateral-flow diagnostics, plate-reader enzyme immunoassay, and direct tissue culture cytotoxici

73 ) were positive for human lymphotropic virus enzyme immunoassay, and none of 2,831 were positive for

74 road range of enteropathogens using culture, enzyme immunoassay, and PCR.

75 PCR, the production of resolvin D1 (RvD1) by enzyme immunoassay, and the cognitive status by MMSE.

76 easles, mumps, and rubella was measured with enzyme immunoassays, and the avidity of these antibodies

77 seronegative than from the ART-Def group by enzyme immunoassay (ART-96W 49 [46%] of 107 vs ART-Def e

78 gh-disease-burden population in Malawi using enzyme immunoassay as the gold standard diagnostic test.

79 negative Coccidioides serology determined by enzyme immunoassay at presentation.

80 was 74.8% (95% CI, -8.2% to 94.1%) using an enzyme immunoassay-based case definition and 85.1% (95%

81 Most commercially available enzyme immunoassay-based methods have limited sensitivit

82 detected by RNA-based screening coupled with enzyme immunoassay-based testing.

83 eloped an immunoglobulin G (IgG)-capture BED-enzyme immunoassay (BED-CEIA) to identify recent human i

84 Samples were tested with the BED capture enzyme immunoassay (BED-CEIA) which measures the proport

85 HIV incidence that includes the BED capture enzyme immunoassay (BED-CEIA), an antibody avidity assay

86 d a robust MAA that includes the BED capture enzyme immunoassay (BED-CEIA), the Bio-Rad Avidity assay

87 In addition, new enzyme immunoassays can quantify hepatitis B surface and

88 ed using 3 serologic assays: the BED capture enzyme immunoassay (CEIA), the Bio-Plex (Luminex) assay,

89 d one particular treponemal immunoassay (eg, enzyme immunoassays, chemiluminescence immunoassays, mic

90 en quantified through competitive inhibition enzyme immunoassay (CIEIA), showed maximum production at

91 clusion, we expect that ODI chemiluminescent enzyme immunoassays (CLEIAs) using a couple of enzymes c

92 and Shiga toxin-producing E. coli (STEC; by enzyme immunoassay), Clostridium difficile (by cytotoxic

93 ence with the HIV-1 limiting antigen avidity enzyme immunoassay combined with viral load and examined

94 Enzyme immunoassay detection of anti-HCV antibodies in s

95 Laboratory confirmation was made by enzyme immunoassay detection of rotavirus antigen in sto

96 Enzyme immunoassay determined LTB4, and enzyme-linked im

97 used an Ebola virus glycoprotein IgG capture enzyme immunoassay developed from a previously validated

98 pecimens were strongly rotavirus positive by enzyme immunoassay, displayed VP6 subgroup II specificit

99 m was compared to a Abbott second-generation enzyme immunoassay (EIA 2.0).

100 nc., Buffalo Grove, IL) and compared with an enzyme immunoassay (EIA) (Abbott Laboratories) licensed

101 tive samples were tested for Shiga toxins by enzyme immunoassay (EIA) (ImmunoCard STAT! enterohemorrh

102 specimens, which were also tested for Stx by enzyme immunoassay (EIA) (ProSpecT STEC; Remel, Lenexa,

103 immunoglobulin G (IgG) level was measured by enzyme immunoassay (EIA) and by plaque reduction neutral

104 We compared paired enzyme immunoassay (EIA) and latex agglutination (LA) as

105 wo-test algorithm: an initial screen with an enzyme immunoassay (EIA) and reflex testing of EIA-react

106 (VLPs) and compared their antigenicities by enzyme immunoassay (EIA) and surrogate antibody neutrali

107 been tested previously with the GP5+/6+ PCR enzyme immunoassay (EIA) and the GP5+/6+ PCR LMNX assay

108 Stool was tested for C. difficile by toxin enzyme immunoassay (EIA) and toxigenic culture (TC).

109 sults by a Campylobacter-specific commercial enzyme immunoassay (EIA) and, less so, a research PCR we

110 ifficile infections (CDIs) detected by toxin enzyme immunoassay (EIA) are more severe and have worse

111 t as an alternative for the more established enzyme immunoassay (EIA) detection of 14 targeted high-r

112 CTTT) for Lyme disease includes a first-tier enzyme immunoassay (EIA) followed by a supplemental immu

113 c testing protocol for Lyme disease (LD), an enzyme immunoassay (EIA) followed by immunoglobulin M an

114 ed to that of a multistep algorithm using an enzyme immunoassay (EIA) for detection of glutamate dehy

115 The clinical utility of Platelia Aspergillus enzyme immunoassay (EIA) for galactomannan (GM) antigen

116 .e., sorbitol-MacConkey (SMAC) agar culture, enzyme immunoassay (EIA) for Shiga toxin, or the simulta

117 ompared with a less sensitive (LS) (detuned) enzyme immunoassay (EIA) for their abilities to distingu

118 Enzyme immunoassay (EIA) for toxins A/B is too insensiti

119 The commercially-available C6 Lyme enzyme immunoassay (EIA) has been approved to replace th

120 mon US Food and Drug Administration-approved enzyme immunoassay (EIA) HIV antibody kits were used to

121 inexpensive, commercially available heparin enzyme immunoassay (EIA) kit that has a limit of detecti

122 era were blinded and sent with galactomannan enzyme immunoassay (EIA) kits to the participating labor

123 Antibody detection by enzyme immunoassay (EIA) may increase sensitivity and pe

124 ositive stool tests for toxins A and/or B by enzyme immunoassay (EIA) or tcdB by polymerase chain rea

125 Campylobacter antigen detection by enzyme immunoassay (EIA) provides rapid results compared

126 deleterious implications of a Campylobacter enzyme immunoassay (EIA) result and the increasing impor

127 NN performed quantitative predictions of the enzyme immunoassay (EIA) Signal/Cutoff (S/Co) profiles f

128 pared to results from routine culture and an enzyme immunoassay (EIA) specific for the recovery and i

129 supplanted by the more rapid and inexpensive enzyme immunoassay (EIA) technique.

130 be an unacceptable number of false-positive enzyme immunoassay (EIA) test results for IgM among pers

131 ty, finding 5.5% reactive Treponema pallidum enzyme immunoassay (EIA) tests.

132 d (BDD) electrodes and a competitive magneto-enzyme immunoassay (EIA) that enables high sensitivity.

133 gorithm where the first tier is typically an enzyme immunoassay (EIA) that if positive or equivocal i

134 zes a first-tier immunofluorescence assay or enzyme immunoassay (EIA) that, if the result is positive

135 The addition of toxin enzyme immunoassay (EIA) to nucleic acid amplification t

136 on by reverse transcriptase PCR (RT-PCR) and enzyme immunoassay (EIA) were similar, but 18% of health

137 We used an amplified enzyme immunoassay (EIA) with a reduced-cutoff "negative

138 we describe a highly sensitive and specific enzyme immunoassay (EIA) with chemically modified, multi

139 TLV-1 and HTLV-2 antibodies were measured by enzyme immunoassay (EIA) with confirmation by immunofluo

140 ng 2 incidence assays, a less-sensitive (LS) enzyme immunoassay (EIA), and the BED assay.

141 assay (ELISA), the Axiom Diagnostics HEV IgG enzyme immunoassay (EIA), and the Mikrogen recomLine HEV

142 a dual glutamate dehydrogenase and toxin A/B enzyme immunoassay (EIA), and the RTCA assay.

143 oplasma galactomannan (GM) in urine using an enzyme immunoassay (EIA), and we showed low positive agr

144 scharge were tested in viral neutralization, enzyme immunoassay (EIA), and Western immunoblot tests a

145 HIV-Selectest is a serodiagnostic enzyme immunoassay (EIA), containing p6 and gp41 peptide

146 The methods included enzyme immunoassay (EIA), direct cytotoxin testing, and

147 tration-approved serologic tests, such as an enzyme immunoassay (EIA), followed by Western blot testi

148 )) by Western blotting (WB), antigen capture enzyme immunoassay (EIA), immunohistochemistry (IHC), an

149 en that can be detected in stool by culture, enzyme immunoassay (EIA), or PCR.

150 the SRA and an anti-PF4/heparin IgG-specific enzyme immunoassay (EIA), testing serial serum samples i

151 e sensitive than the widely used solid-phase enzyme immunoassay (EIA), the Premier toxin A and B EIA

152 e dehydrogenase (GDH) assay, a toxin A and B enzyme immunoassay (EIA), the Xpert C. difficile assay,

153 l-time PCR tests, toxin antigen detection by enzyme immunoassay (EIA), toxigenic culture, and fecal c

154 Assays to measure antibody include the enzyme immunoassay (EIA), which measures immunoglobulin

155 ns isolated from Clostridium difficile toxin enzyme immunoassay (EIA)-positive fecal samples from Oxf

156 and all results were verified by a standard enzyme immunoassay (EIA).

157 19 years old were tested for EBV antibody by enzyme immunoassay (EIA).

158 and the outbreak virus Iowa-G/USA-06 and by enzyme immunoassay (EIA).

159 re tested for mumps immunoglobulin (Ig) G by enzyme immunoassay (EIA).

160 staglandin E2 (PGE2) levels were measured by enzyme immunoassay (EIA).

161 edictive value was 90% compared with 76% for enzyme immunoassay (EIA).

162 d serum cryptococcal antigen testing with an enzyme immunoassay (EIA).

163 standard comparator test (SCT), the GP5+/6+ enzyme immunoassay (EIA).

164 es in titers of antibody to hRSV and hMPV by enzyme immunoassay (EIA).

165 Testing was performed using an HEV IgG enzyme immunoassay (EIA, Axiom Diagnostics), and the rec

166 e United States are transitioning from toxin enzyme immunoassays (EIA) to nucleic acid amplification

167 hat of at least one comparator method; toxin enzyme immunoassays (EIA), glutamate dehydrogenase (GDH)

168 ty assays has been largely replaced by rapid enzyme immunoassays (EIA).

169 ed for the development of antibody detection enzyme immunoassays (EIA).

170 lity is determined primarily by results from enzyme immunoassays (EIA).

171 jirebio Diagnostics, Malvern, PA], Trep-Sure enzyme immunoassay [EIA; Phoenix Biotech, Oakville, Onta

172 equence algorithm; discordant results (e.g., enzyme immunoassay [EIA] reactive and reactive plasma re

173 reactivity of the IDEIA Norovirus assay (an enzyme immunoassay [EIA]) in a prospective and retrospec

174 obe-based species identification system (PCR-enzyme immunoassay [EIA]) was then used to resolve these

175 glutination assay (TPPA); and (7) Trep-Sure (enzyme immunoassay [EIA]), using a reference standard co

176 sponse (by serotonin-release assay [SRA] and enzyme-immunoassay [EIA]), and the frequency of recurren

177 andard, cytotoxicity assay, we studied three enzyme immunoassays (EIAs) and one rapid EIA, which demo

178 Currently, culture and enzyme immunoassays (EIAs) are the primary methods used

179 G avidity and epitope type specificity (ETS) enzyme immunoassays (EIAs) for distinguishing past from

180 Recently, several commercially available enzyme immunoassays (EIAs) have been developed for the d

181 om stool specimens and have combined it with enzyme immunoassays (EIAs) in a three-step protocol.

182 We used enzyme immunoassays (EIAs) to measure HHV-8 antibodies (

183 ducted to evaluate the performances of three enzyme immunoassays (EIAs) utilizing one or more conform

184 2007) to correlate physician use of O&P and enzyme immunoassays (EIAs) with the yield of parasites d

185 those of three C. difficile toxin-detecting enzyme immunoassays (EIAs), an EIA for the detection of

186 tested for IgM by both indirect and capture enzyme immunoassays (EIAs), and oral fluids were tested

187 eas HCV-specific antibodies were assessed in enzyme immunoassays (EIAs), chemiluminescent assays, and

188 logical screening, typically performed using enzyme immunoassays (EIAs), is invasive, sometimes socia

189 e in Australia were compared to a commercial enzyme immunoassay (ELISA) and a recently described nove

190 es for nucleic acid amplification tests, but enzyme immunoassays, even after negative-gray-zone testi

191 ingle-cell migration, immunoblotting, ELISA, enzyme immunoassay), ex vivo (rat aortic ring assay), an

192 characteristic plot showed that autoantibody enzyme immunoassay exhibited 90% sensitivity and 88% spe

193 o the standard two-tiered testing algorithm (enzyme immunoassay followed by Western blot).

194 All discordant cases were retested with an enzyme immunoassay followed by Western blotting, and fiv

195 l stool samples were collected and tested by enzyme immunoassay for Campylobacter Stool and blood sam

196 mpared our two-step diagnostic algorithm, an enzyme immunoassay for glutamate dehydrogenase (GDH) fol

197 etecting toxigenic Clostridium difficile: an enzyme immunoassay for glutamate dehydrogenase antigen (

198 of a commercially available, rapid membrane enzyme immunoassay for influenza A and B virus detection

199 scrapes using a C. trachomatis-specific PCR-enzyme immunoassay for the MOMP-1 gene.

200 m samples from these subjects were tested by enzyme immunoassay for total antibodies to HEV.

201 C. difficile latex agglutination, an enzyme immunoassay for toxins A and B or glutamate dehyd

202 Monoclonal antibody-based enzyme immunoassays for Ara h 1, Ara h 2, and Ara h 6 we

203 s has been made with regard to the design of enzyme immunoassays for IFN-gamma, this assay is still l

204 est Nile virus-specific IgM and indirect IgG enzyme immunoassays for the detection of IgG antibodies

205 Recently, immunoglobulin M (IgM)-capture enzyme immunoassays for the detection of West Nile virus

206 fungus-specific primers and DNA probes in an enzyme immunoassay format (PCR-EIA).

207 reported that the Aspergillus galactomannan enzyme immunoassay (GM EIA) may be a useful diagnostic t

208 red the diagnostic yields of a galactomannan enzyme immunoassay (GM EIA), quantitative real-time PCR

209 evaluated the performance of a galactomannan enzyme immunoassay (GM EIA; Bio-Rad) by using a range of

210 tion available on inclusion of galactomannan enzyme immunoassay (GM-EIA) (2002) and beta-d-glucan (20

211 The galactomannan enzyme immunoassay (GM-EIA) is widely utilized for the d

212 al diagnostics, differences in galactomannan enzyme immunoassay (GM-EIA) performance have been report

213 s B virus (HBV) antibodies and galactomannan enzyme immunoassay (GM-EIA) positivity.

214 Based on BKV-specific IgG enzyme immunoassay >/=8 units, subjects were divided int

215 Initially, the Focus and PANBIO IgM enzyme immunoassays had at least 95% agreement, sensitiv

216 present study developed a novel HCV antigens enzyme immunoassay (HCV-Ags EIA) and assessed its sensit

217 eek 84 using three assays: fourth-generation enzyme immunoassay HIV antigen-antibody combination, HIV

218 oth free and labeled ALP as a Raman probe in enzyme immunoassays, immunoblotting, and DNA hybridizati

219 ntly released IMMY Aspergillus galactomannan enzyme immunoassay (IMMY GM-EIA) when testing serum samp

220 ulin M and G antibodies were demonstrated by enzyme immunoassay in 8% and 85%, respectively.

221 ent, and detection of rotavirus infection by enzyme immunoassay in at least 100 children <5 years of

222 evels were tested by immunocytochemistry and enzyme immunoassay in BALB/c and B6 corneas.

223 say was more sensitive than the conventional enzyme immunoassay in buffer (IC(50) = 0.1 and 2 microg/

224 nce of rotavirus, as determined by Rotaclone enzyme immunoassay, in adults who had stools submitted f

225 Subsequent chemiluminescence enzyme immunoassays indicated that they were positive fo

226 chemiluminescent biosensor and conventional enzyme immunoassay indicates that the accurate, precise,

227 The Platelia galactomannan enzyme immunoassay is a commercially available noncultur

228 active treponemal chemiluminescence assay or enzyme immunoassay is low if the epidemiological risk an

229 Two-step testing with a toxin enzyme immunoassay is recommended to discriminate betwee

230 ercially available affinity purification and enzyme immunoassay kit and found both assays to be in ag

231 The Wampole C. difficile Tox A/B II enzyme immunoassay kit was used.

232 All samples were analyzed with two different enzyme immunoassay kits to gauge assay sensitivity to me

233 utility of SMAC to that of the Premier EHEC enzyme immunoassay (Meridian Diagnostics) for detection

234 ificity and sensitivity of this autoantibody enzyme immunoassay method were compared with the convent

235 Despite the high sensitivity of the enzyme immunoassay method, it is more expensive and has

236 Both DCP and AFP were tested using enzyme immunoassay methods.

237 tly recovered or deceased), serum testing by enzyme immunoassay offers a new and practical diagnostic

238 The MVista anti-Coccidioides antibody enzyme immunoassay offers improved sensitivity, compared

239 r optimizing the sensitivity of an amplified enzyme immunoassay on vulvovaginal-swab specimens.

240 cies were detected by commercially available enzyme immunoassays on stool samples.

241 Some individuals shed virus detected by enzyme immunoassay or genotyping reverse transcription p

242 value of repeat testing for C. difficile by enzyme immunoassay or PCR.

243 ; 4 specimens were positive for rotavirus by enzyme immunoassay or PCR.

244 l event, with rotavirus detected in stool by enzyme immunoassay or reverse transcription-polymerase c

245 blished infection, as identified by standard enzyme immunoassay or Western blot analysis, appeared in

246 y using comparative metabolomic analysis and enzyme-immunoassay, our results reveal that normal fibro

247 T, or the Premier C. difficile toxin A and B enzyme immunoassay [P-EIA]).

248 ed to those of a colorimetric microtiter PCR enzyme immunoassay (PCR-EIA) used as a diagnostic assay.

249 Adult toxin enzyme immunoassay-positive CDI cases in a population of

250 for enteropathogens on stools from rotavirus enzyme immunoassay-positive diarrhea episodes and all se

251 All C. difficile toxin enzyme-immunoassay-positive and culture-positive samples

252 easures, ward-based contact with symptomatic enzyme-immunoassay-positive patients cannot account for

253 analyzed with SLA/LP-overlapping peptides in enzyme immunoassay, proliferation, and enzyme-linked imm

254 The enzyme immunoassay ratio decreased in controllers who ha

255 87 or 2006 strains either reduced or ablated enzyme immunoassay recognition by the GII.4-2002-specifi

256 The samples were analyzed with fluorescence enzyme immunoassays recognizing domestic mite allergens

257 orins, which reflected the rates of use; the enzyme immunoassay replaced the cytotoxin assay because

258 orary techniques, such as immunoblotting and enzyme immunoassays, require extensive sample manipulati

259 els were measured by colorimetric assays and enzyme immunoassay, respectively.

260 media were measured with Northern blots and enzyme immunoassays, respectively.

261 and inflammatory biomarkers were measured by enzyme immunoassay.RESULTSSixty-nine participants (97% m

262 d in the testing of >3,000 antigen-positive (enzyme immunoassay) samples collected during clinical tr

263 were compared to those of a third-generation enzyme immunoassay screen with confirmation of repeat re

264 P) examinations, and Giardia/Cryptosporidium enzyme immunoassay screens (GC-EIA) performed for patien

265 e by the "fourth-generation" HIV-1 screening enzyme immunoassay (targeting the p24 antigen and anti-H

266 Repeat enzyme immunoassay testing for C. difficile toxin has be

267 Sensitive/less sensitive enzyme immunoassay testing is an effective tool for asse

268 ssification of discordant results using CrAg enzyme immunoassay testing, the sensitivity was 98.1% (9

269 g with the increased availability and use of enzyme immunoassay testing, which detects the presence o

270 rithm with repeated sensitive-less-sensitive enzyme immunoassay tests was also evaluated.

271 ed, with the use of sensitive-less-sensitive enzyme immunoassay tests, as recent infections.

272 y nonbronchoscopic bronchoalveolar lavage by enzyme immunoassay, tissue culture, and RT-PCR.

273 tates were tested with the BED HIV-1 capture enzyme immunoassay to classify infections as recent or l

274 a solid phase for developing a sandwich-type enzyme immunoassay to detect C-reactive protein (CRP) us

275 TARHS methodology uses the BED HIV-1 capture enzyme immunoassay to determine recent HIV infections by

276 tested their sera using a BED HIV-1 capture enzyme immunoassay to estimate HIV incidence.

277 We used an enzyme immunoassay to measure anti-HEV immunoglobulin G

278 Here, we used enzyme immunoassay to measure fecal glucocorticoid metab

279 ncidence attributable to changing from toxin enzyme immunoassays to NAAT.

280 A cap fluorescence enzyme immunoassay using the serum of the patient showed

281 In the present study, an enzyme immunoassay using viruslike particles (VLPs) was

282 d and confirmed by pull-down experiments and enzyme immunoassays using recombinant LcrH-2 and LcrE.

283 erially during therapy using a microparticle enzyme immunoassay validated with in-house reference sta

284 MBL, and antibody serology were analyzed by enzyme-immunoassays; viral load by PCR.

285 An in vitro enzyme immunoassay was established with monoclonal antib

286 The HCV enzyme immunoassay was reported positive in 1590 (12%) p

287 Enzyme immunoassay was used to analyze measles virus-spe

288 A mumps virus-specific enzyme immunoassay was used to measure the seroprevalenc

289 By using enzyme immunoassay, we show uptake of NE, probably throu

290 easures primarily IgG antibodies) and an IgG enzyme immunoassay were found useful for very early diag

291 tes that were tested positive by a Rotaclone enzyme immunoassay were submitted to the Centers for Dis

292 Participants who were positive by HCV enzyme immunoassay were tested for HCV viremia by a bran

293 The INFLU A.B-Quick and Directigen Flu A+B enzyme immunoassays were compared with direct immunofluo

294 ive glutamate dehydrogenase and toxin A or B enzyme immunoassays) were randomly assigned (1:1) with a

295 at were positive in the Platelia Aspergillus enzyme immunoassay when initially tested.

296 .S. patients and 288 Japanese patients using enzyme immunoassay with different preparations of high-m

297 cation test and a polymer conjugate-enhanced enzyme immunoassay with negative-gray-zone testing.

298 SP-1(19) IgG or IgG subclass Abs measured by enzyme immunoassay with six different recombinant MSP-1(

299 cells expressing lytic viral proteins and by enzyme immunoassays with recombinant viral structural pr

300 -generation Murex HIV Ag/Ab Combination EIA (enzyme immunoassay) within an adolescent and young-adult